Various pharmaceutical means are being developed to inhibit PCSK9.6 These include small monobodies, oral peptides, antisense oligonucleotides, and
small interfering ribonucleic acid (SIRNA).
APN401 is an individual adoptive cell therapy in which human peripheral blood mononuclear cells are silenced ex- vivo for Cbl-b (an E3 ubiquitin ligase) using
small interfering ribonucleic acid (siRNA), thereby activating them to fight cancer more efficiently.
Various methods to inhibit apoptosis including the cell surface Fas receptor (FAS) pathway inhibitors (also known as CD95L pathway inhibitor), caspase inhibitors, overexpression of anti-apoptotic genes and
small interfering ribonucleic acid (RNA) therapy are discussed.
